AmerisourceBergen Corporation – Company Information
AmerisourceBergen Corporation is a multinational pharmaceutical services company, based in Chesterbrook, Pennsylvania, USA. It is publicly traded on the New York Stock Exchange (NYSE) under the stock ticker symbol ‘ABC’.
The company focuses on providing drug distribution services for pharmaceutical manufacturers and healthcare providers, designed to reduce costs and improve patient outcomes.
Approximately one fifth of pharmaceuticals sold and distributed in the US are handled by AmerisourceBergen.
It was formed in 2001 after the merger of Bergen Brunswig Corporation and AmeriSource Health Corporation.
Its pharmaceutical distribution business is operated under the following business units:
Drug Corporation: providing pharmaceuticals, staffing, pharmacy automation and professional consultation services.
Speciality Group: in oncology, plasma-derivative and biotech product distribution.
Consulting Services: partners with manufacturers to prove product value and expand market access.
World Courier: specialty logistics for global clinical trials delivering fully-integrated GxP-compliant temperature-controlled transport, distribution and storage solutions.
- President and CEO: Steven H. Collis
- Chairman: Richard C. Gozon
- Industry: Pharmaceuticals
- Type: Public
- Listed on the New York Stock Exchange (NYSE)
- NYSE stock symbol: ABC
- S&P 500 Component
- Revenue: $119.569 billion USD (2014)
- Net income: $276.484 million USD (2014)
- Diluted earnings per share: $1.17 USD (2014)
- Company head office: 1300 Morris Drive Chesterbrook, PA 19087.5594
- Employees: 14,000 (2014)
- Website: http://www.amerisourcebergen.com/
- Investor relations contact number: 610-727-7000
- Investor relations email: firstname.lastname@example.org
AmerisourceBergen Corporation Financial Results, Years Ended September 30
|Operating data (in $ thousands)||2014||2013|
|Cost of goods sold||$116,586,761||$85,451,348|
|Distribution, selling and administrative expenses||$1,587,261||$1,333,712|
|Income from continuing operations||$284,030||$493,435|
|Balance sheet data (in $ thousands)|
|Total stockholders’ equity||$1,956,899||$2,319,745|
|Common share data (in $)|
|Basic earnings per share||$1.22||$1.88|
|Diluted earnings per share||$1.17||$1.84|
|Cash flow data (in $ thousands)|
|Net cash provided by operating activities||$1,463,153||$788,125|
|Net cash provided by (used for) investing activities||$(384,155)||$117,260|
|Net cash used for financing activities||$(501,491)||$(740,987)|
|Cash and cash equivalents at beginning of year||$1,231,006||$1,006,608|
|Cash and cash equivalents at end of year||$1,808,513||$1,231,006|